Nitta Gelatin India Ltd. has announced the appointment of Dr. Balu Paulose Maliakel as an Additional Director on its Board, effective from May 25, 2026. The decision was taken during a Board meeting held on the same day, based on the recommendation of the Nomination and Remuneration Committee. Dr. Maliakel is designated to serve as a Non-Executive Independent Director for a term of five years, effective from the date of the ensuing Annual General Meeting, subject to shareholder approval.

The appointment was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company confirmed that Dr. Maliakel is not related to any Director, Key Managerial Personnel, or Promoters of the company. Furthermore, he is not debarred from accessing the capital markets or restrained from holding the position of Director in any listed entity by any regulatory authority.

Dr. Balu Paulose Maliakel is a seasoned scientist and industry leader with over 30 years of experience in natural ingredients, nutraceuticals, and herbal extract research. He previously served as the Managing Director & CEO of Akay Natural Ingredients Pvt. Ltd., where he played a key role in driving the company's growth in natural food colours and nutraceuticals. He currently serves as a Non-Executive Director at the same company.

Key Details of Appointment

Throughout his career, Dr. Maliakel has held senior R&D and technical leadership roles at AVT Natural Products Ltd., Akay Flavours & Aromatics Pvt. Ltd., and Kancor Flavours & Extracts. He also gained international research experience as a Post-Doctoral Research Associate at the Universities of Vienna and Zurich.

Nitta Gelatin India Limited announced its audited standalone and consolidated financial results for the quarter and year ended 31 March 2026, reporting strong growth in both revenue and profitability. The Board of Directors approved the results at their meeting held on 2 May 2026, and the company subsequently published newspaper advertisements in English and Malayalam newspapers pursuant to Regulation 30 and Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

For the financial year ended 31 March 2026, the company reported revenue from operations of ₹58,830.85 lakh, compared to ₹52,744.84 lakh in the previous year. Total income for FY26 stood at ₹61,408.59 lakh, an increase from ₹53,742.67 lakh in FY25. Net profit for the year rose to ₹11,058.99 lakh, representing a 34.5% growth over the previous year's net profit of ₹8,220.72 lakh.

Annual Financial Highlights

The following table summarises the key standalone financial metrics for the year:

Quarterly Performance

In the quarter ended 31 March 2026, revenue from operations reached ₹16,173.49 lakh, while total income stood at ₹16,659.20 lakh. The company reported a net profit of ₹3,400.75 lakh for the quarter, compared to ₹1,917.08 lakh in the corresponding quarter of the previous year. The table below presents a sequential and year-on-year comparison of key standalone quarterly metrics:

Balance Sheet Position

As at 31 March 2026, the company's total assets stood at ₹56,998.81 lakh, compared to ₹49,154.50 lakh in the previous year. Equity share capital remained unchanged at ₹907.92 lakh, while other equity (reserves excluding revaluation reserves) increased to ₹48,595.89 lakh from ₹38,327.42 lakh. Total equity reached ₹49,503.81 lakh, up from ₹39,235.34 lakh in FY25.

Dividend Recommendation

The Board of Directors has recommended a dividend of ₹7 per equity share (70% of the face value of ₹10 per share) for declaration at the forthcoming Annual General Meeting. Additionally, the Board proposed a dividend of ₹0.7650 per preference share (@ 7.65063% p.a.) on 44,44,444 redeemable preference shares of ₹10 each. Both recommendations are subject to shareholder approval.

Consolidated Results

On a consolidated basis, including subsidiary Bamni Proteins Limited, total income for FY26 stood at ₹60,096.09 lakh. Net profit from continuing operations after tax stood at ₹9,824.56 lakh, while the discontinued operations of the subsidiary recorded a net loss after tax of ₹104.83 lakh, resulting in a consolidated net profit of ₹9,719.74 lakh. Consolidated reserves (excluding revaluation reserves) stood at ₹50,217.33 lakh as at 31 March 2026. The consolidated basic and diluted EPS from continuing and discontinued operations was ₹107.11.

The subsidiary's operations have been classified as discontinued operations following the decision to permanently close its manufacturing unit. Assets held for sale from the subsidiary amounted to ₹530.38 lakh as at 31 March 2026. Other income for FY26 includes ₹1,312.50 lakh being dividend income received from the subsidiary company.

Regulatory and Other Developments

During the year, the Government of India consolidated 29 existing labour legislations into four labour codes effective 21 November 2025. Pursuant to this, the company recognised an incremental liability of ₹226.33 lakh for own employees as employee benefit expense for the nine months ended 31 December 2025. Additionally, during the quarter ended 31 March 2026, a provision of ₹41 lakh was accumulated based on the evaluation of gratuity liability for contract workforce. Separately, a customs duty matter involving a demand of ₹877.15 lakh and a penalty of ₹1,091.21 lakh remains under adjudication before the Hon'ble Supreme Court of India, with the company maintaining a contingent liability of ₹1,819.66 lakh and a provision for customs duty of ₹148.70 lakh pending disposal of the petition.